Working... Menu

Haemorrhage Alleviation With Tranexamic Acid- Intestinal System (HALT-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01658124
Recruitment Status : Recruiting
First Posted : August 6, 2012
Last Update Posted : December 11, 2018
Global trial which will include about 40 countries and over 200 hospitals
Information provided by (Responsible Party):
London School of Hygiene and Tropical Medicine

Brief Summary:
Severe bleeding in the digestive system is a common symptom of many diseases. Each year, about 50,000 people end up in British hospitals because of this problem and about 5,000 of them die. The most common cause of this bleeding is stomach ulcers. In sub-Saharan Africa, schistosomiasis (parasitic worms) is responsible for about 130,000 deaths from stomach bleeding each year. From previous research in other bleeding conditions such as surgery and trauma, we know that a drug called tranexamic acid can reduce bleeding and save lives. We now want to do the HALT-IT trial to see if giving tranexamic acid can save lives and if there are any complications in people with severe bleeding from the digestive system.

Condition or disease Intervention/treatment Phase
Gastrointestinal Bleeding Drug: Tranexamic Acid Drug: Placebo Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial
Actual Study Start Date : July 2013
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tranexamic acid
(total dose 8 grams)
Drug: Tranexamic Acid
Placebo Comparator: Placebo
(Sodium Chloride 0.9%)
Drug: Placebo

Primary Outcome Measures :
  1. The primary outcome is death in hospital (cause-specific mortality will also be recorded - haemorrhage, myocardial infarction, stroke, pulmonary embolism, pneumonia, malignancy, other) [ Time Frame: within 28 days of randomisation ]

Secondary Outcome Measures :
  1. Re-bleeding [ Time Frame: within 28 days of randomisation ]
  2. Need for salvage surgery or radiological intervention [ Time Frame: within 28 days of randomisation ]
  3. Blood transfusion - blood or blood component units transfused [ Time Frame: within 28 days of randomisation ]
  4. Thromboembolic events (myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis) [ Time Frame: within 28 days of randomisation ]
  5. Other adverse medical events (including renal failure, significant cardiac event, respiratory failure, hepatic failure, sepsis, pneumonia, seizure) [ Time Frame: within 28 days of randomisation ]
  6. Functional status measured using the Katz Index of Independence in Activities of Daily Living [ Time Frame: within 28 days of randomisation ]
  7. Time spent at an intensive care unit [ Time Frame: within 28 days of randomisation ]
  8. Length of stay in hospital [ Time Frame: within 28 days of randomisation ]
  9. Patient status (death, hospital readmission) [ Time Frame: within 12 months of randomisation ]
    Limited to recruiting countries with appropriate databases

  10. Death from haemorrhage [ Time Frame: within 28 days of randomisation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients
  • with acute significant upper or lower gastrointestinal bleeding
  • where the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents in the patient

Exclusion Criteria:

  • The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular patient with upper or lower gastrointestinal bleeding.
  • There are no other exclusions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01658124

Layout table for location contacts
Contact: Haleema Shakur ++44(0)20 7958 8113

Layout table for location information
United Kingdom
Over 50 countries Worldwide Recruiting
London, United Kingdom
Principal Investigator: Tim Harris, MD         
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
Global trial which will include about 40 countries and over 200 hospitals
Layout table for investigator information
Study Director: Haleema Shakur LSHTM

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: London School of Hygiene and Tropical Medicine Identifier: NCT01658124     History of Changes
Other Study ID Numbers: ISRCTN11225767
First Posted: August 6, 2012    Key Record Dates
Last Update Posted: December 11, 2018
Last Verified: December 2018

Keywords provided by London School of Hygiene and Tropical Medicine:
haemorrhage,antifibrinolytic, clinical trial,

Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action